HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Thomas Ichim, Ph.D., SpinalCyte’s Chief Scientific Officer, will present at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting (ISASS19) on Thursday, April 4, 2019 at 7:50 a.m. PDT in Anaheim, CA.
The presentation entitled, “Double Blind Placebo Controlled Clinical Trial of Universal Donor Fibroblast Product CybroCell™ for Treatment of Disc Degenerative Disease,” will include updates from SpinalCyte’s Phase I/II clinical trial for CybroCell™ including new 16-month data. Previously presented 12-month pain and MRI data showed continued pain relief and improved disc heights. Recent clearance by the FDA for SpinalCyte’s Investigational New Drug protocol has paved the way for the company’s continued clinical trials and commercialization of its fibroblast cell therapy.
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
CybroCell™ is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated sustained improvement in pain relief and mobility beyond the 12-month endpoint.
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc regeneration using human dermal fibroblasts. Currently, SpinalCyte holds 39 U.S. and international issued patents and has filed for an additional 100+ patents across a variety of disease pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.